Table 1 |
|||
|
Patient characteristics |
|||
|
Parameter |
All SSc (n = 26) |
Diffuse cutaneous SSc (n = 6) |
Limited cutaneous SSc (n = 20) |
|
|
|||
|
Age (years) |
56 ± 13 (32 to 75) |
50 ± 9 (40 to 66) |
46 ± 14 (32 to 75) |
|
Sex (% female) |
77 |
67 |
80 |
|
Disease duration (years) |
7.9 ± 5.3 (1 to 19) |
7.7 ± 6.0 (3 to 19) |
8.0 ± 5.2 (1 to 18) |
|
Modified Rodnan skin score |
8.3 ± 6.1 (2 to 19) |
16.3 ± 3.3 (12 to 19) |
5.8 ± 4.3† (2 to 18) |
|
Organ and tissue involvement |
|||
|
Pulmonary fibrosis |
11 (42) |
6 (100) |
5 (25)** |
|
Pulmonary hypertension |
5 (19) |
3 (50) |
2 (10) |
|
Cardiac involvement |
6 (23) |
1 (17) |
5 (25) |
|
Gastrointestinal involvement |
2 (8) |
1 (17) |
1 (5) |
|
Active digital ulcer |
7 (27) |
0 (0) |
7 (30) |
|
History of digital ulcer |
16 (62) |
4 (83) |
12 (55) |
|
Arteriosclerotic disease |
3 (12) |
0 (0) |
3 (15) |
|
ESR (mm/hour) |
19 ± 14 |
28 ± 20 |
16 ± 11 |
|
Antinuclear antibody positivity |
23 (89) |
5 (83) |
18 (90) |
|
Anti-centromere antibody |
11 (42) |
0 (0) |
11 (55)* |
|
Anti-Scl70 antibody |
9 (35) |
2 (33) |
7 (35) |
|
Medication |
|||
|
Immunomodulatory druga |
10 (38) |
2 (33) |
8 (40) |
|
Steroids |
6 (23) |
1 (17) |
5 (25) |
|
Iloprost |
12 (46) |
3 (50) |
9 (45) |
|
Calcium-channel blockers |
9 (35) |
2 (33) |
7 (35) |
|
Betablockers |
1 (4) |
0 (0) |
1 (5) |
|
Bosentan |
7 (27) |
3 (50) |
4 (20) |
|
Sildenafil |
3 (12) |
0 (0) |
3 (15) |
|
Low-dose aspirin |
5 (19) |
0 (0) |
5 (25) |
|
RAMRIS |
6.5 ± 4.7 (0 to 14) |
5.4 ± 4.1 (1 to 12) |
7.0 ± 5.0 (0 to 14) |
|
Radiographs of the hands |
21 (81) |
4 (67) |
17 (85) |
|
Signs of arthritis |
2 (10) |
0 (0) |
2 (12) |
|
Acroosteolysis |
9 (43) |
2 (50) |
7 (41) |
|
Soft-tissue calcifications |
11 (52) |
1 (25) |
10 (59) |
|
FFbH (% functional capacity) |
68.7 ± 22.8 (33 to 100) |
58.2 ± 25.2 (39 to 100) |
71.9 ± 21.7 (33 to 100) |
|
Health Assessment Questionnaireb |
1.24 ± 0.64 (0.36 to 2.25) |
1.54 ± 0.7 (0.36 to 2.08) |
1.15 ± 0.61 (0.36 to 2.25) |
|
|
|||
|
Data presented as mean ± standard deviation (range) or n (%). Only the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for the clinically dominantly affected hand was analyzed. Percentages were rounded. ESR, erythrocyte sedimentation rate (Westergren's method); FFbH, Funktionsfragebogen Hannover (German-language standardized assessment questionnaire on physical function); SSc, systemic sclerosis. Significant differences: *P < 0.05 and **P < 0.01 between the groups with limited and diffuse skin disease as assessed by Fisher's exact test; †P < 0.01 as assessed by the Mann-Whitney U test. All other comparisons were nonsignificant. aIncluding methotrexate, leflunomide, mycophenolate, etanercept, and cyclophosphamide. bValues calculated from the FFbH using the formula: HAQ = 3.16 - (0.028 × FFbH)). |
|||
|
Akbayrak et al. Arthritis Research & Therapy 2013 15:R2 doi:10.1186/ar4128 |
|||
